spacer
home > ict > spring 2020 > from zero to sixty: why yesterday’s eclinical trial horizon is today’s reality
PUBLICATIONS
International Clinical Trials

From Zero to Sixty: Why Yesterday’s eClinical Trial Horizon Is Today’s Reality






On 11 March 2020, WHO officially declared the rapidly spreading COVID-19 outbreak as a pandemic. The first in years, this pandemic caused the world to change its social behaviours in just a few weeks. Now, living in a post-COVID-19 society, several industries have been forced to stress test the capabilities of their remote work environment. The clinical trials industry is no exception. As a result, ideas that were once touted as ‘next generation’ during keynotes just a few years ago are now being put to the test in live trial environments. However, it’s not just the ‘shiny and new’ technologies on the front lines of post- COVID-19 trials. Instead, it’s a unique blend of eClinical technologies, new and old. This mix, combined with strong processes and quick thinking, has helped lay the foundation for our industry’s rapid pivot towards remote work.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the company

The best technology succeeds in the background. Signant Health provides solutions that simplify every step of the patient journey to make it easier for people to participate in, and for sites and study teams to run, clinical trials. Signant unites eCOA, eConsent, patient engagement, interactive response technology, clinical supplies, and endpoint quality into the industry’s most comprehensive patient-centric suite – an evolution built on more than 20 years of proven clinical research technology. Our intense focus on the patient experience, deep therapeutic area expertise, and global operational scale enable hundreds of sponsors and CROs (including all top 20 pharmaceutical companies) to extend the reach of drug development, expand patient opportunities, and improve data quality – helping them bring lifechanging therapies to our families and communities around the world.

hello@signanthealth.com

www.signanthealth.com
Print this page
Send to a friend
Privacy statement
News and Press Releases

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole

LONDON, UK, 17 June 2022 – Otsuka Pharmaceutical Europe Ltd. (“Otsuka”) and H. Lundbeck A/S (“Lundbeck”) today announce that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for aripiprazole as a 2-month ready-to-use (RTU) long-acting injectable (LAI) for the maintenance treatment of schizophrenia in adult patients stabilised with aripiprazole.
More info >>

White Papers

Recommendations Sourcing Human Biospecimens

BioIVT

The foundations for protecting human research subjects come from the ethical principles surrounding the Belmont report : Respect for persons, beneficence, and justice. The use of human biospecimens in research supports these principles with legal and ethical regulations - the most important of which is permission.(1) This permission may come directly from the donor or granted by others with authorization to protect the interests of biospecimen donors.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement